Payment overview · 2025
General Payments
$897.60
50 reported records · 12 companies
Healthcare provider profile · identity verified
Thomas Peters, MD
Allopathic & Osteopathic Physicians|Internal Medicine · HENDERSON, NV · NPI 1659432250
Verified facts
What the public records show
CMS Open Payments records show Thomas Peters, MD received $897.60 in general payments during 2025 across 50 reported records.
AstraZeneca Pharmaceuticals LP accounted for 28.6% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 16 associated products.
A separate comparison found the same explicitly named product in public Medicare Part D data: Farxiga.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported LINZESS as an associated drug or biological on 87954 records involving 21815 distinct recipient NPIs. Public Medicare Part D data also shows 14 claims for Linzess by this doctor in 2024.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported SYNTHROID as an associated drug or biological on 10655 records involving 4881 distinct recipient NPIs. Public Medicare Part D data also shows 13 claims for Synthroid by this doctor in 2024.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported BRILINTA as an associated drug or biological on 993 records involving 512 distinct recipient NPIs. Public Medicare Part D data also shows 16 claims for Brilinta by this doctor in 2024.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported FARXIGA as an associated drug or biological on 106133 records involving 42906 distinct recipient NPIs. Public Medicare Part D data also shows 21 claims for Farxiga by this doctor in 2024.
Novo Nordisk Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Ozempic as an associated drug or biological on 261625 records involving 77793 distinct recipient NPIs. Public Medicare Part D data also shows 43 claims for Ozempic by this doctor in 2024.
PFIZER INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported ELIQUIS as an associated drug or biological on 87112 records involving 36032 distinct recipient NPIs. Public Medicare Part D data also shows 112 claims for Eliquis by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| AstraZeneca Pharmaceuticals LP | Unresolved — no canonical attribution shown | $257.09 | 28.6% | 14 | 2025 |
| Novo Nordisk Inc | Unresolved — no canonical attribution shown | $205.48 | 22.9% | 9 | 2025 |
| Boehringer Ingelheim Pharmaceuticals, Inc. | Unresolved — no canonical attribution shown | $157.57 | 17.6% | 11 | 2025 |
| Abbott Laboratories | Unresolved — no canonical attribution shown | $118.98 | 13.3% | 7 | 2025 |
| PFIZER INC. | Unresolved — no canonical attribution shown | $31.58 | 3.5% | 2 | 2025 |
| ABBVIE INC. | Unresolved — no canonical attribution shown | $27.53 | 3.1% | 1 | 2025 |
| Exact Sciences Corporation | Unresolved — no canonical attribution shown | $20.59 | 2.3% | 1 | 2025 |
| GlaxoSmithKline, LLC. | Unresolved — no canonical attribution shown | $17.59 | 2.0% | 1 | 2025 |
| Phathom Pharmaceuticals, Inc. | Unresolved — no canonical attribution shown | $17.40 | 1.9% | 1 | 2025 |
| Daiichi Sankyo Inc. | Unresolved — no canonical attribution shown | $15.10 | 1.7% | 1 | 2025 |
| Amgen Inc. | Unresolved — no canonical attribution shown | $14.86 | 1.7% | 1 | 2025 |
| ViiV Healthcare Company | Unresolved — no canonical attribution shown | $13.83 | 1.5% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $897.60 | 50 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| Wegovy Normalized: wegovy |
Drug | Novo Nordisk Inc | $205.48 | 9 | 2025 |
Source payment records
|
|||||
| AIRSUPRA Normalized: airsupra |
Drug | AstraZeneca Pharmaceuticals LP | $180.52 | 9 | 2025 |
Source payment records
|
|||||
| JARDIANCE Normalized: jardiance |
Drug | Boehringer Ingelheim Pharmaceuticals, Inc. | $157.57 | 11 | 2025 |
Source payment records
|
|||||
| FARXIGA Normalized: farxiga |
Drug | AstraZeneca Pharmaceuticals LP | $135.77 | 6 | 2025 |
Source payment records
|
|||||
| FREESTYLE LIBRE 3 Normalized: freestyle libre 3 |
Device | Abbott Laboratories | $118.98 | 7 | 2025 |
Source payment records
|
|||||
| NURTEC ODT Normalized: nurtec odt |
Drug | PFIZER INC. | $31.58 | 2 | 2025 |
Source payment records
|
|||||
| ZAVZPRET Normalized: zavzpret |
Drug | PFIZER INC. | $31.58 | 2 | 2025 |
Source payment records
|
|||||
| QULIPTA Normalized: qulipta |
Drug | ABBVIE INC. | $27.53 | 1 | 2025 |
Source payment records
|
|||||
| UBRELVY Normalized: ubrelvy |
Drug | ABBVIE INC. | $27.53 | 1 | 2025 |
Source payment records
|
|||||
| Cologuard Collection Kit Normalized: cologuard collection kit |
Device | Exact Sciences Corporation | $20.59 | 1 | 2025 |
Source payment records
|
|||||
| TRELEGY ELLIPTA Normalized: trelegy ellipta |
Drug | GlaxoSmithKline, LLC. | $17.59 | 1 | 2025 |
Source payment records
|
|||||
| VOQUEZNA Normalized: voquezna |
Drug | Phathom Pharmaceuticals, Inc. | $17.40 | 1 | 2025 |
Source payment records
|
|||||
| INJECTAFER Normalized: injectafer |
Drug | Daiichi Sankyo Inc. | $15.10 | 1 | 2025 |
Source payment records
|
|||||
| OTEZLA Normalized: otezla |
Drug | Amgen Inc. | $14.86 | 1 | 2025 |
Source payment records
|
|||||
| REPATHA Normalized: repatha |
Biological | Amgen Inc. | $14.86 | 1 | 2025 |
Source payment records
|
|||||
| APRETUDE Normalized: apretude |
Drug | ViiV Healthcare Company | $13.83 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
| Open Payments product | Payment year | Part D brand | Part D year | Claims | Match method | Source |
|---|---|---|---|---|---|---|
| FARXIGA farxiga |
2025 | Farxiga | 2024 | 21 Beneficiary count suppressed |
exact normalized | Medicare Part D |
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | LINZESS open payments reported associated product |
CMS Open Payments — General Payments 87954 supporting records · 21815 recipient NPIs · example record 1201352608 |
Linzess · 2024 Exact normalized brand match · 1 Part D row |
14 | suppressed by CMS |
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | SYNTHROID open payments reported associated product |
CMS Open Payments — General Payments 10655 supporting records · 4881 recipient NPIs · example record 1201352636 |
Synthroid · 2024 Exact normalized brand match · 1 Part D row |
13 | suppressed by CMS |
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | BRILINTA open payments reported associated product |
CMS Open Payments — General Payments 993 supporting records · 512 recipient NPIs · example record 1206131430 |
Brilinta · 2024 Exact normalized brand match · 1 Part D row |
16 | suppressed by CMS |
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | FARXIGA open payments reported associated product |
CMS Open Payments — General Payments 106133 supporting records · 42906 recipient NPIs · example record 1206131362 |
Farxiga · 2024 Exact normalized brand match · 1 Part D row |
21 | suppressed by CMS |
| Novo Nordisk Inc Exact reporting entity; no affiliate inference |
2025 | Ozempic open payments reported associated product |
CMS Open Payments — General Payments 261625 supporting records · 77793 recipient NPIs · example record 1188130076 |
Ozempic · 2024 Exact normalized brand match · 1 Part D row |
43 | suppressed by CMS |
| PFIZER INC. Exact reporting entity; no affiliate inference |
2025 | ELIQUIS open payments reported associated product |
CMS Open Payments — General Payments 87112 supporting records · 36032 recipient NPIs · example record 1228794063 |
Eliquis · 2024 Exact normalized brand match · 1 Part D row |
112 | 19 |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Atorvastatin Calcium | Atorvastatin Calcium | 262 | 73 |
| Lisinopril | Lisinopril | 208 | 53 |
| Amlodipine Besylate | Amlodipine Besylate | 196 | 50 |
| Simvastatin | Simvastatin | 189 | 50 |
| Levothyroxine Sodium | Levothyroxine Sodium | 171 | 47 |
| Metformin Hcl | Metformin Hcl | 166 | 40 |
| Meloxicam | Meloxicam | 158 | 44 |
| Pantoprazole Sodium | Pantoprazole Sodium | 153 | 42 |
| Losartan Potassium | Losartan Potassium | 140 | 38 |
| Eliquis | Apixaban | 112 | 19 |
| Montelukast Sodium | Montelukast Sodium | 103 | 26 |
| Omeprazole | Omeprazole | 98 | 32 |
| Hydrochlorothiazide | Hydrochlorothiazide | 92 | 28 |
| Metoprolol Tartrate | Metoprolol Tartrate | 92 | 22 |
| Zolpidem Tartrate | Zolpidem Tartrate | 92 | 15 |
| Sertraline Hcl | Sertraline Hcl | 84 | 20 |
| Rosuvastatin Calcium | Rosuvastatin Calcium | 83 | 26 |
| Gabapentin | Gabapentin | 78 | 16 |
| Tamsulosin Hcl | Tamsulosin Hcl | 78 | 23 |
| Metoprolol Succinate | Metoprolol Succinate | 72 | 18 |
| Albuterol Sulfate Hfa | Albuterol Sulfate | 70 | 19 |
| Ibuprofen | Ibuprofen | 62 | 19 |
| Clonazepam | Clonazepam | 61 | suppressed |
| Trazodone Hcl | Trazodone Hcl | 61 | 14 |
| Carvedilol | Carvedilol | 56 | 16 |
| Furosemide | Furosemide | 55 | 17 |
| Losartan-Hydrochlorothiazide | Losartan/Hydrochlorothiazide | 53 | 15 |
| Lisinopril-Hydrochlorothiazide | Lisinopril/Hydrochlorothiazide | 52 | 14 |
| Azithromycin | Azithromycin | 46 | 34 |
| Pravastatin Sodium | Pravastatin Sodium | 45 | 13 |
| Clopidogrel | Clopidogrel Bisulfate | 43 | suppressed |
| Ozempic | Semaglutide | 43 | suppressed |
| Allopurinol | Allopurinol | 38 | suppressed |
| Mounjaro | Tirzepatide | 37 | suppressed |
| Escitalopram Oxalate | Escitalopram Oxalate | 36 | suppressed |
| Atenolol | Atenolol | 34 | suppressed |
| Triamcinolone Acetonide | Triamcinolone Acetonide | 34 | 14 |
| Alprazolam | Alprazolam | 32 | suppressed |
| Ezetimibe | Ezetimibe | 31 | 11 |
| Famotidine | Famotidine | 31 | 11 |
| Citalopram Hbr | Citalopram Hydrobromide | 30 | suppressed |
| Venlafaxine Hcl Er | Venlafaxine Hcl | 30 | suppressed |
| Clonidine Hcl | Clonidine Hcl | 29 | suppressed |
| Piroxicam | Piroxicam | 29 | 11 |
| Finasteride | Finasteride | 28 | suppressed |
| Fluticasone Propionate | Fluticasone Propionate | 27 | suppressed |
| Prednisone | Prednisone | 26 | 15 |
| Alendronate Sodium | Alendronate Sodium | 25 | suppressed |
| Glimepiride | Glimepiride | 25 | suppressed |
| Metformin Hcl Er | Metformin Hcl | 25 | suppressed |
| Cyclobenzaprine Hcl | Cyclobenzaprine Hcl | 24 | suppressed |
| Farxiga | Dapagliflozin Propanediol | 21 | suppressed |
| Januvia | Sitagliptin Phosphate | 21 | suppressed |
| Levofloxacin | Levofloxacin | 21 | 18 |
| Celecoxib | Celecoxib | 20 | suppressed |
| Olmesartan Medoxomil | Olmesartan Medoxomil | 20 | suppressed |
| Potassium Chloride | Potassium Chloride | 20 | suppressed |
| Fenofibrate | Fenofibrate Nanocrystallized | 19 | suppressed |
| Ropinirole Hcl | Ropinirole Hcl | 19 | suppressed |
| Hydroxyzine Hcl | Hydroxyzine Hcl | 18 | suppressed |
| Isosorbide Mononitrate Er | Isosorbide Mononitrate | 18 | suppressed |
| Verapamil Er | Verapamil Hcl | 18 | suppressed |
| Telmisartan | Telmisartan | 17 | suppressed |
| Tramadol Hcl | Tramadol Hcl | 17 | suppressed |
| Amoxicillin-Clavulanate Potass | Amoxicillin/Potassium Clav | 16 | 11 |
| Brilinta | Ticagrelor | 16 | suppressed |
| Glipizide Er | Glipizide | 16 | suppressed |
| Nifedipine Er | Nifedipine | 16 | suppressed |
| Nystatin | Nystatin | 16 | suppressed |
| Pioglitazone Hcl | Pioglitazone Hcl | 16 | suppressed |
| Sildenafil Citrate | Sildenafil Citrate | 16 | suppressed |
| Xarelto | Rivaroxaban | 16 | suppressed |
| Ciprofloxacin Hcl | Ciprofloxacin Hcl | 15 | 13 |
| Paroxetine Hcl | Paroxetine Hcl | 15 | suppressed |
| Temazepam | Temazepam | 15 | suppressed |
| Testosterone Cypionate | Testosterone Cypionate | 15 | suppressed |
| Tretinoin | Tretinoin | 15 | suppressed |
| Acyclovir | Acyclovir | 14 | suppressed |
| Duloxetine Hcl | Duloxetine Hcl | 14 | suppressed |
| Estradiol | Estradiol | 14 | suppressed |
| Linzess | Linaclotide | 14 | suppressed |
| Valacyclovir | Valacyclovir Hcl | 14 | suppressed |
| Benazepril Hcl | Benazepril Hcl | 13 | suppressed |
| Pregabalin | Pregabalin | 13 | suppressed |
| Quetiapine Fumarate | Quetiapine Fumarate | 13 | suppressed |
| Synthroid | Levothyroxine Sodium | 13 | suppressed |
| Zolpidem Tartrate Er | Zolpidem Tartrate | 13 | suppressed |
| Amiodarone Hcl | Amiodarone Hcl | 12 | suppressed |
| Doxazosin Mesylate | Doxazosin Mesylate | 12 | suppressed |
| Eszopiclone | Eszopiclone | 12 | suppressed |
| Nebivolol Hcl | Nebivolol Hcl | 12 | suppressed |
| Donepezil Hcl | Donepezil Hcl | 11 | suppressed |
| Mirtazapine | Mirtazapine | 11 | suppressed |
| Warfarin Sodium | Warfarin Sodium | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $897.60 · 50 records | AstraZeneca Pharmaceuticals LP | AIRSUPRA, APRETUDE, Cologuard Collection Kit, FARXIGA, FREESTYLE LIBRE 3, INJECTAFER, JARDIANCE, NURTEC ODT, OTEZLA, QULIPTA, REPATHA, TRELEGY ELLIPTA, UBRELVY, VOQUEZNA, Wegovy, ZAVZPRET | 6 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- What role, if any, does Farxiga play in your treatment recommendations for me?
- How do you evaluate evidence when you have a financial relationship with ABBVIE INC.?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error